30-Second Takeaway
- Early-life bifidobacteria metabolites associate with reduced food sensitization and atopic dermatitis risk.
- Tezepelumab improves severe asthma and nasal polyp outcomes and reduces steroid burden in real-world practice.
- Pediatric FPIAP with atopic features and IgE sensitization tends to acquire cow’s-milk tolerance later.
- Sampling site critically shapes detection of TH2 and tissue-resident T cells in asthma research.
- Microbiota, probiotics, diet, and pollutants modulate type 2 inflammation across skin, gut, and lung.
Week ending January 17, 2026
Microbiota, tissue-resident type 2 immunity, and environment: practical levers for allergy and airway disease care
Early aromatic-lactate–producing bifidobacteria link to lower food sensitization and eczema
In this 147-child birth cohort followed to age 5, early colonization with aromatic lactate–producing bifidobacteria associated with lower allergic outcomes. Vaginal delivery, older siblings, and exclusive breastfeeding for 2 months promoted transmission of these strains and higher gut aromatic lactate levels. This microbiota–metabolite pattern inversely correlated with food allergen–specific IgE through 5 years and atopic dermatitis at 2 years. Mechanistically, 4‑hydroxy-phenyllactate suppressed IgE, but not IgG, production in ex vivo human immune cell cultures.
Residency time and niche cues drive eosinophil specialization across tissues
This mouse single-cell and proteomic atlas shows eosinophil identity is shaped by tissue-derived signals and local residency duration. Long-lived small-intestinal eosinophils diversify into distinct phenotypic subsets, while lung and colonic populations remain comparatively uniform. Trajectory-associated surface markers map maturation from bone marrow progenitors to long-term tissue-resident eosinophils. These molecular tools can help resolve eosinophil states in specific organs, informing interpretation of anti-eosinophil therapies.
Tezepelumab benefits upper and lower airways in severe asthma regardless of nasal polyps
This multicenter real-world study followed severe asthma patients on tezepelumab for 6 months, including many with CRSwNP. Tezepelumab significantly and rapidly improved nasal outcomes (SNOT-22, VAS, nasal polyp score) and asthma measures (ACT, lung function). Oral corticosteroid use, hospitalizations, and exacerbations decreased over follow-up, indicating substantial steroid-sparing and clinical benefit. Treatment responses were similar in patients with and without CRSwNP, supporting tezepelumab for unified airway disease phenotypes.
References
Numbered in order of appearance. Click any reference to view details.
Additional Reads
Optional additional studies from this edition.